FibroGen Financials

29 M

Revenue Q2, 2017

3.5 B

Mkt cap, 13-Nov-2017
Net income (Q2, 2017)(33.2 M)
EBIT (Q2, 2017)(31.4 M)
Cash, 30-Jun-2017290.3 M

Market Value

Revenue/Financials

Income Statement

Annual

USDFY, 2015FY, 2016

Revenue

180.8 m179.6 m

Revenue growth, %

(1%)

R&D expense

214.1 m187.2 m

General and administrative expense

44.4 m46 m

Operating expense total

258.5 m233.2 m

EBIT

(77.6 m)(53.7 m)

EBIT margin, %

(43%)(30%)

Interest expense

11 m10.7 m

Pre tax profit

(85.5 m)(61.8 m)

Income tax expense

242 k(71 k)

Net Income

(85.8 m)(61.7 m)

Quarterly

USDQ1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017

Revenue

16.3 m120.6 m19.5 m28.3 m89.3 m30.1 m26.9 m29 m

R&D expense

50.5 m51.6 m52.1 m43.7 m52.4 m40.6 m46.7 m47 m

General and administrative expense

10.5 m9.7 m11.2 m11.4 m10.4 m11.6 m11.5 m13.4 m

Operating expense total

61 m61.2 m63.3 m55.1 m62.8 m52.2 m58.3 m60.4 m

EBIT

(44.7 m)59.3 m(43.8 m)(26.8 m)26.5 m(22.1 m)(31.4 m)(31.4 m)

EBIT margin, %

(274%)49%(224%)(95%)30%(73%)(117%)(108%)

Interest expense

2.8 m2.8 m2.8 m2.8 m2.4 m2.8 m2.4 m2.8 m

Interest income

843 k707 k1.5 m

Pre tax profit

(46.6 m)57.3 m(45.1 m)(28.1 m)24.2 m(24 m)(33.1 m)(33.1 m)

Income tax expense

(113 k)158 k60 k48 k

Net Income

(46.4 m)57.1 m(45.1 m)(27.8 m)24.3 m(24.2 m)(33.2 m)(33.2 m)

Balance Sheet

Annual

USDFY, 2015FY, 2016

Cash

153.3 m173.8 m

Accounts Receivable

15.4 m10.4 m

Inventories

4 m2.9 m

Current Assets

200.6 m266.5 m

PP&E

129 m123.7 m

Total Assets

470.6 m469.6 m

Accounts Payable

6.5 m6.2 m

Current Liabilities

67.2 m65.1 m

Total Liabilities

294.4 m

Additional Paid-in Capital

586.6 m625.9 m

Retained Earnings

(408.1 m)(469.7 m)

Total Equity

177.6 m155.8 m

Financial Leverage

2.7 x3 x

Quarterly

USDQ1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017

Cash

128.4 m236.5 m208.7 m141 m190.4 m198.3 m170.6 m290.3 m

Accounts Receivable

7 m12.2 m7.4 m5.9 m18.1 m7.7 m7.2 m8.9 m

Current Assets

155.4 m263.6 m232.6 m184 m252.3 m253.5 m256.6 m371.3 m

PP&E

131.7 m130.5 m129.6 m127.6 m126.3 m124.8 m122.8 m122.6 m

Total Assets

435.5 m541.4 m499.2 m442.5 m499.1 m486.2 m441.8 m542.6 m

Accounts Payable

2.4 m3.9 m4.2 m1.5 m3.5 m2 m3 m3.3 m

Current Liabilities

54 m63.5 m59 m58.3 m66.4 m61.7 m60.1 m59.8 m

Total Liabilities

231.7 m268.5 m262.7 m266.3 m286.8 m288.6 m290.8 m293.3 m

Additional Paid-in Capital

553.4 m565.2 m575 m593.9 m605.1 m614.8 m635 m766.9 m

Retained Earnings

(368.7 m)(311.6 m)(356.7 m)(435.9 m)(411.6 m)(435.7 m)(502.9 m)(536.1 m)

Total Equity

203.9 m272.9 m217.3 m157 m193.1 m178.3 m131.7 m230.1 m

Financial Leverage

2.1 x2 x2.3 x2.8 x2.6 x2.7 x3.4 x2.4 x

Cash Flow

Annual

USDFY, 2015FY, 2016

Net Income

(85.8 m)(61.7 m)

Depreciation and Amortization

5.7 m6 m

Accounts Receivable

(2 m)5 m

Inventories

978 k1.1 m

Accounts Payable

2 m(298 k)

Cash From Operating Activities

(18.6 m)7.1 m

Purchases of PP&E

(2 m)(1.3 m)

Cash From Investing Activities

(5.9 m)6.6 m

Cash From Financing Activities

12.3 m6.7 m

Quarterly

USDQ1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017

Net Income

(46.4 m)10.7 m(34.4 m)(27.8 m)(3.5 m)(27.7 m)(33.2 m)(66.3 m)

Depreciation and Amortization

2.8 m4.2 m1.5 m3 m4.5 m1.5 m3.1 m

Accounts Receivable

7 m1.3 m6.1 m9.5 m(2.7 m)7.7 m3.2 m1.5 m

Accounts Payable

2.4 m(636 k)(317 k)(5 m)(3 m)(4.5 m)(3.3 m)(3 m)

Cash From Operating Activities

58.9 m20.7 m(17.3 m)27.4 m25.7 m(27.1 m)(46.9 m)

Purchases of PP&E

(989 k)(1.7 m)(898 k)(1 m)(1.1 m)(636 k)(1.6 m)

Cash From Investing Activities

6 m14.3 m5.1 m7.2 m15.7 m23.4 m40.3 m

Cash From Financing Activities

5.4 m8.2 m(149 k)2.5 m3.6 m574 k123 m

Ratios

Y, 2017

Financial Leverage

2.4 x

Operating Metrics

FY, 2016

Phase III Trials

1

Phase II Trials

1

Facilities

2

Patent Portfolios

4